Results 1 to 10 of about 3,878 (166)
Clinical Characteristics and Outcomes of 1894 Women with Peripartum Cardiomyopathy Treated with and Without Levosimendan in Germany [PDF]
Journal of Cardiovascular Development and DiseaseBackground: Peripartum cardiomyopathy (PPCM) is a rare form of heart failure occurring during the last month of pregnancy or within five months postpartum.
Jan A. Kloka +9 more
doaj +2 more sources
Levosimendan in Cardiac Surgery
Journal of Cardiothoracic and Vascular Anesthesia, 2005 Levosimendan is a new calcium sensitizer with inodilatory properties. There is growing clinical experience with levosimendan given to cardiac surgical patients. The aim of this report was to evaluate the effects of perioperative use of levosimendan in surgical patients with high perioperative risk, compromised left ventricular (LV) function, or ...
Veli-Pekka Harjola +1 more
exaly +3 more sources
Weaning from invasive ventilation with levosimendan (WEANLESS): study protocol for a multicentre randomised clinical trial [PDF]
BMJ OpenBackground Prolonged weaning from invasive mechanical ventilation is a major challenge in critically ill patients failing a spontaneous breathing trial. Levosimendan, a calcium sensitiser, has been shown to improve respiratory muscle function.
Marcus J Schultz +6 more
doaj +2 more sources
Transdermal delivery of levosimendan
European Journal of Pharmaceutical Sciences, 2000 The aim of this study was to determine if transdermal penetration of levosimendan, a novel positive inotropic drug, could be enhanced and controlled by formulation modifications. Penetration of levosimendan across human epidermis in vitro was determined using abdominal excised skin and diffusion cells.
Arto Urtti +2 more
exaly +3 more sources
Journal of Cardiovascular Development and Disease, 2022 (1) Background: The present study aims to investigate the effect of administration of Levosimendan and Exenatide in various concentrations, as well as of the coadministration of those agents in an ischemia–reperfusion injury isolated heart model.
Vasileios Leivaditis +11 more
doaj +1 more source
BMC Cardiovascular Disorders, 2022 Background Levosimendan can improve clinical symptoms and the cardiorenal rescue success rate, and stabilize hemodynamic parameters in individuals suffering from acute decompensated heart failure.
Miaomiao Li +5 more
doaj +1 more source
Indian Heart Journal, 2021 To assess the clinical outcomes of levosimendan and dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function in Indian scenario.
Basil John, Pharm D +4 more
doaj +1 more source
European Radiology Experimental, 2021 Background We investigated whether levosimendan prevents contrast medium nephrotoxicity with glycerol aggravation in rats. Methods Forty-eight Wistar albino rats were assigned to eight groups (n = 6 × 8).
Irmak Durur-Subasi +6 more
doaj +1 more source
New England Journal of Medicine, 2017 Comment on : Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S, Mason AJ, Cross M, Al-Beidh F, Best-Lane J, Brealey D, Nutt CL, McNamee JJ, Reschreiter H, Breen A, Liu KD, Ashby D. Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. N Engl J Med. 2016 Oct 27;375(17):1638-1648. doi: 10.1056/NEJMoa1609409.
Putzu, Alessandro +2 more
openaire +11 more sources
Biomedicines, 2023 The calcium sensitizer levosimendan is used for the treatment of acute decompensated heart failure. A small portion (4–7%) of levosimendan is metabolized to the pharmacologically active metabolite OR-1896 via the inactive intermediate OR-1855.
Hannah Kipka +4 more
doaj +1 more source